Virtu Financial LLC bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 2,265 shares of the biopharmaceutical company’s stock, valued at approximately $1,013,000.
A number of other institutional investors have also recently bought and sold shares of REGN. Fieldpoint Private Securities LLC bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $130,000. Sterling Investment Advisors Ltd. increased its holdings in shares of Regeneron Pharmaceuticals by 11.2% in the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 28 shares during the last quarter. FNY Partners Fund LP increased its holdings in shares of Regeneron Pharmaceuticals by 200.0% in the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 200 shares during the last quarter. IFP Advisors Inc increased its holdings in shares of Regeneron Pharmaceuticals by 33.2% in the 2nd quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 96 shares during the last quarter. Finally, Vident Investment Advisory LLC bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $200,000. 66.67% of the stock is currently owned by institutional investors and hedge funds.
Shares of Regeneron Pharmaceuticals, Inc. (REGN) opened at $381.32 on Tuesday. The firm has a market cap of $40,910.63, a price-to-earnings ratio of 32.97, a price-to-earnings-growth ratio of 1.50 and a beta of 1.53. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12. Regeneron Pharmaceuticals, Inc. has a 12-month low of $340.09 and a 12-month high of $543.55.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.83 by $0.16. The business had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.45 billion. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The firm’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.13 EPS. equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 13.55 earnings per share for the current fiscal year.
In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,500 shares of the company’s stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $475.00, for a total value of $712,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Charles A. Baker sold 2,000 shares of the company’s stock in a transaction on Friday, September 29th. The stock was sold at an average price of $450.00, for a total transaction of $900,000.00. Following the completion of the transaction, the director now owns 11,000 shares of the company’s stock, valued at $4,950,000. The disclosure for this sale can be found here. Corporate insiders own 10.80% of the company’s stock.
A number of equities analysts have recently commented on the stock. Citigroup reissued a “buy” rating and issued a $575.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, September 7th. Raymond James Financial reissued an “outperform” rating and issued a $566.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, September 6th. Morgan Stanley reissued an “equal weight” rating and issued a $450.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 23rd. BidaskClub raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 24th. Finally, J P Morgan Chase & Co reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 15th. Two equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $467.84.
TRADEMARK VIOLATION WARNING: This story was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/12/virtu-financial-llc-invests-1-01-million-in-regeneron-pharmaceuticals-inc-regn-stock.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.